Publications | Centre for Tuberculosis Research

2022

Drug exposure and susceptibility of second-line drugs correlate with treatment response in patients with multidrug-resistant tuberculosis: a multicentre prospective cohort study in China.
Zheng X, Davies Forsman L, Bao Z, Xie Y, Ning Z, Schön T, Bruchfeld J, Xu B, Alffenaar JW, Hu Y
Eur Respir J 2022;59:3

Detection and isolation of airborne SARS-CoV-2 in a hospital setting.
Rufino de Sousa N, Steponaviciute L, Margerie L, Nissen K, Kjellin M, Reinius B, Salaneck E, Udekwu KI, Rothfuchs AG
Indoor Air 2022;32:3

Programme costs of longer and shorter tuberculosis drug regimens and drug import: a modelling study for Karakalpakstan, Uzbekistan.
Kohler S, Sitali N, Achar J, Paul N
ERJ Open Res 2022;8:1

Cyclooxygenase-Derived Prostaglandin E₂ Drives IL-1-Independent Mycobacterium bovis Bacille Calmette-Guérin-Triggered Skin Dendritic Cell Migration to Draining Lymph Node.
Krmeská V, Aggio JB, Nylén S, Wowk PF, Rothfuchs AG
J Immunol 2022;208:11

2021

High Dimensional Immune Profiling Reveals Different Response Patterns in Active and Latent Tuberculosis Following Stimulation With Mycobacterial Glycolipids.
Silva CS, Sundling C, Folkesson E, Fröberg G, Nobrega C, Canto-Gomes J, Chambers BJ, Lakshmikanth T, Brodin P, Bruchfeld J, Nigou J, Correia-Neves M, Källenius G
Front Immunol 2021;12:

Evaluation of the latent tuberculosis screening and treatment strategy for asylum seekers in Stockholm, Sweden 2015-2018: a record linkage study of the care cascade.
Nederby Öhd J, Hergens MP, Luksha Y, Buxbaum C, Shedrawy J, Jonsson J, Bruchfeld J, Lönnroth K
Eur Respir J 2021;57:3

Genotypic Resistance of Pyrazinamide but Not Minimum Inhibitory Concentration Is Associated With Longer Time to Sputum Culture Conversion in Patients With Multidrug-resistant Tuberculosis.
Kuhlin J, Davies Forsman L, Mansjö M, Jonsson Nordvall M, Wijkander M, Wagrell C, Jonsson J, Groenheit R, Werngren J, Schön T, Bruchfeld J
Clin Infect Dis 2021;73:9

Drug Exposure and Minimum Inhibitory Concentration Predict Pulmonary Tuberculosis Treatment Response.
Zheng X, Bao Z, Forsman LD, Hu Y, Ren W, Gao Y, Li X, Hoffner S, Bruchfeld J, Alffenaar JW
Clin Infect Dis 2021;73:9

Suboptimal moxifloxacin and levofloxacin drug exposure during treatment of patients with multidrug-resistant tuberculosis: results from a prospective study in China.
Davies Forsman L, Niward K, Kuhlin J, Zheng X, Zheng R, Ke R, Hong C, Werngren J, Paues J, Simonsson USH, Eliasson E, Hoffner S, Xu B, Alffenaar JW, Schön T, Hu Y, Bruchfeld J
Eur Respir J 2021;57:3

Drug exposure of first-line anti-tuberculosis drugs in China: A prospective pharmacological cohort study.
Gao Y, Davies Forsman L, Ren W, Zheng X, Bao Z, Hu Y, Bruchfeld J, Alffenaar JW
Br J Clin Pharmacol 2021;87:3

Cost-effectiveness of the latent tuberculosis screening program for migrants in Stockholm Region.
Shedrawy J, Deogan C, Öhd JN, Hergens MP, Bruchfeld J, Jonsson J, Siroka A, Lönnroth K
Eur J Health Econ 2021;22:3

Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort.
Koirala S, Borisov S, Danila E, Mariandyshev A, Shrestha B, Lukhele N, Dalcolmo M, Shakya SR, Miliauskas S, Kuksa L, Manga S, Aleksa A, Denholm JT, Khadka HB, Skrahina A, Diktanas S, Ferrarese M, Bruchfeld J, Koleva A, Piubello A, Koirala GS, Udwadia ZF, Palmero DJ, Munoz-Torrico M, Gc R, Gualano G, Grecu VI, Motta I, Papavasileiou A, Li Y, Hoefsloot W, Kunst H, Mazza-Stalder J, Payen MC, Akkerman OW, Bernal E, Manfrin V, Matteelli A, Mustafa Hamdan H, Nieto Marcos M, Cadiñanos Loidi J, Cebrian Gallardo JJ, Duarte R, Escobar Salinas N, Gomez Rosso R, Laniado-Laborín R, Martínez Robles E, Quirós Fernandez S, Rendon A, Solovic I, Tadolini M, Viggiani P, Belilovski E, Boeree MJ, Cai Q, Davidavičienė E, Forsman LD, De Los Rios J, Drakšienė J, Duga A, Elamin SE, Filippov A, Garcia A, Gaudiesiute I, Gavazova B, Gayoso R, Gruslys V, Jonsson J, Khimova E, Madonsela G, Magis-Escurra C, Marchese V, Matei M, Moschos C, Nakčerienė B, Nicod L, Palmieri F, Pontarelli A, Šmite A, Souleymane MB, Vescovo M, Zablockis R, Zhurkin D, Alffenaar JW, Caminero JA, Codecasa LR, García-García JM, Esposito S, Saderi L, Spanevello A, Visca D, Tiberi S, Pontali E, Centis R, D'Ambrosio L, van den Boom M, Sotgiu G, Migliori GB
Pulmonology 2021;27:5

Tuberculosis in Biologic-naïve Patients With Rheumatoid Arthritis: Risk Factors and Tuberculosis Characteristics.
Sundbaum JK, Arkema EV, Bruchfeld J, Jonsson J, Askling J, Baecklund E
J Rheumatol 2021;48:8

Additional drug resistance for Mycobacterium tuberculosis during turnaround time for drug-susceptibility testing in China: A multicenter observational cohort study.
Zhu J, Bao Z, Xie Y, Werngren J, Hu Y, Davies Forsman L, Bruchfeld J, Hoffner S
Int J Infect Dis 2021;108:

Emergence of additional drug resistance during treatment of multidrug-resistant tuberculosis in China: a prospective cohort study.
Hu Y, Zheng X, Davies Forsman L, Ning Z, Chen C, Gao Y, Zhang Z, Lu W, Werngren J, Bruchfeld J, Hoffner S, Xu B
Clin Microbiol Infect 2021;27:12

The Impact of Borderline Quantiferon-TB Gold Plus Results for Latent Tuberculosis Screening under Routine Conditions in a Low-Endemicity Setting.
Wikell A, Jonsson J, Dyrdak R, Henningsson AJ, Eringfält A, Kjerstadius T, Hålldin E, Baqir H, Kholod V, Sturegård E, Bruchfeld J, Schön T
J Clin Microbiol 2021;59:12

Accuracy of molecular drug susceptibility testing amongst tuberculosis patients in Karakalpakstan, Uzbekistan.
Gil H, Margaryan H, Azamat I, Ziba B, Bayram H, Nazirov P, Gomez D, Singh J, Zayniddin S, Parpieva N, Achar J
Trop Med Int Health 2021;26:4

Vaccinia Virus Infection Inhibits Skin Dendritic Cell Migration to the Draining Lymph Node.
Aggio JB, Krmeská V, Ferguson BJ, Wowk PF, Rothfuchs AG
J Immunol 2021;206:4

High-dimensional profiling reveals phenotypic heterogeneity and disease-specific alterations of granulocytes in COVID-19.
Lourda M, Dzidic M, Hertwig L, Bergsten H, Palma Medina LM, Sinha I, Kvedaraite E, Chen P, Muvva JR, Gorin JB, Cornillet M, Emgård J, Moll K, García M, Maleki KT, Klingström J, Michaëlsson J, Flodström-Tullberg M, Brighenti S, Buggert M, Mjösberg J, Malmberg KJ, Sandberg JK, Henter JI, Folkesson E, Gredmark-Russ S, Sönnerborg A, Eriksson LI, Rooyackers O, Aleman S, Strålin K, Ljunggren HG, Björkström NK, Svensson M, Ponzetta A, Norrby-Teglund A, Chambers BJ, Karolinska KI/K COVID-19 Study Group.
Proc Natl Acad Sci U S A 2021;118:40

2020

Stabilization of blood for long-term storage can affect antibody-based recognition of cell surface markers.
Silva MH, Lepzien R, Ols S, Dahlberg B, Grunewald J, Loré K, Smed-Sörensen A, Correia-Neves M, Empadinhas N, Färnert A, Källenius G, Sundling C
J Immunol Methods 2020;481-482:

Editorial: Mycobacterial Glycolipids-Role in Immunomodulation and Targets for Vaccine Development.
Källenius G, Nigou J, Cooper A, Correia-Neves M
Front Immunol 2020;11:

Increased risk of active tuberculosis during pregnancy and postpartum: a register-based cohort study in Sweden.
Jonsson J, Kühlmann-Berenzon S, Berggren I, Bruchfeld J
Eur Respir J 2020;55:3

Screening and treatment of tuberculosis among pregnant women in Stockholm, Sweden, 2016-2017.
Fröberg G, Jansson L, Nyberg K, Obasi B, Westling K, Berggren I, Bruchfeld J
Eur Respir J 2020;55:3

Latent tuberculosis in pregnant women: a patient perspective.
Jansson L, Shedrawy J, Lönnroth K, Bruchfeld J, Kulane A
Int J Tuberc Lung Dis 2020;24:3

Improved treatment outcome of multidrug-resistant tuberculosis with the use of a rapid molecular test to detect drug resistance in China.
Shi W, Davies Forsman L, Hu Y, Zheng X, Gao Y, Li X, Jiang W, Bruchfeld J, Diwan VK, Hoffner S, Xu B
Int J Infect Dis 2020;96:

Prospective evaluation of improving fluoroquinolone exposure using centralised therapeutic drug monitoring (TDM) in patients with tuberculosis (PERFECT): a study protocol of a prospective multicentre cohort study.
van den Elsen SH, Sturkenboom MG, Akkerman O, Barkane L, Bruchfeld J, Eather G, Heysell SK, Hurevich H, Kuksa L, Kunst H, Kuhlin J, Manika K, Moschos C, Mpagama SG, Muñoz Torrico M, Skrahina A, Sotgiu G, Tadolini M, Tiberi S, Volpato F, van der Werf TS, Wilson MR, Zúñiga J, Touw DJ, Migliori GB, Alffenaar JW
BMJ Open 2020;10:6

Treatment quality and outcome for multidrug-resistant tuberculosis patients in four regions of China: a cohort study.
Zheng XB, Diwan VK, Zhao Q, Hu Y, Bruchfeld J, Jiang WL, Hoffner S, Xu B
Infect Dis Poverty 2020;9:1

CD4⁺ T cell proliferative responses to PPD and CFP-10 associate with recent M. tuberculosis infection.
Borgström EW, Fröberg G, Correia-Neves M, Atterfelt FB, Bellbrant J, Szulkin R, Chryssanthou E, Ängeby K, Tecleab T, Ruhwald M, Andersen P, Källenius G, Bruchfeld J
Tuberculosis (Edinb) 2020;123:

Health-related quality of life among persons treated for tuberculosis in a European setting.
Shedrawy J, Jansson L, Bruchfeld J, Lönnroth K
Int J Tuberc Lung Dis 2020;24:4

[Is it time to use sputum induction as a complementary specimen collection procedure in adult patients with suspected pulmonary tuberculosis?]
Kuhlin J, Tammelin A, Petersson J, Chryssanthou E, Tideholm-Nylén A, Schön T, Bruchfeld J
Lakartidningen 2020;117:

Development and validation of a simple LC-MS/MS method for simultaneous determination of moxifloxacin, levofloxacin, prothionamide, pyrazinamide and ethambutol in human plasma.
Zheng X, Jongedijk EM, Hu Y, Kuhlin J, Zheng R, Niward K, Paues J, Xu B, Davies Forsman L, Schön T, Bruchfeld J, Alffenaar JC
J Chromatogr B Analyt Technol Biomed Life Sci 2020;1158:

Massive and rapid COVID-19 testing is feasible by extraction-free SARS-CoV-2 RT-PCR.
Smyrlaki I, Ekman M, Lentini A, Rufino de Sousa N, Papanicolaou N, Vondracek M, Aarum J, Safari H, Muradrasoli S, Rothfuchs AG, Albert J, Högberg B, Reinius B
Nat Commun 2020;11:1

Operative and Technical Modifications to the Coriolis® µ Air Sampler That Improve Sample Recovery and Biosafety During Microbiological Air Sampling.
Rufino de Sousa N, Shen L, Silcott D, Call CJ, Rothfuchs AG
Ann Work Expo Health 2020;64:8

A fieldable electrostatic air sampler enabling tuberculosis detection in bioaerosols.
Rufino de Sousa N, Sandström N, Shen L, Håkansson K, Vezozzo R, Udekwu KI, Croda J, Rothfuchs AG
Tuberculosis (Edinb) 2020;120:

2019

Lipoarabinomannan in Active and Passive Protection Against Tuberculosis.
Correia-Neves M, Sundling C, Cooper A, Källenius G
Front Immunol 2019;10:

Biomarkers for tuberculosis: the case for lipoarabinomannan.
Correia-Neves M, Fröberg G, Korshun L, Viegas S, Vaz P, Ramanlal N, Bruchfeld J, Hamasur B, Brennan P, Källenius G
ERJ Open Res 2019;5:1

Treatment of latent tuberculosis with 12 weeks isoniazid/rifapentine in clinical practice.
Fröberg G, Jansson L, Bruchfeld J
Eur Respir J 2019;53:2

Mass spectrometry for therapeutic drug monitoring of anti-tuberculosis drugs.
Kuhlin J, Sturkenboom MGG, Ghimire S, Margineanu I, van den Elsen SHJ, Simbar N, Akkerman OW, Jongedijk EM, Koster RA, Bruchfeld J, Touw DJ, Alffenaar JC
Clin Mass Spectrom 2019;14 Pt A:

Minimum Inhibitory Concentrations of Fluoroquinolones and Pyrazinamide Susceptibility Correlate to Clinical Improvement in Multidrug-resistant Tuberculosis Patients: A Nationwide Swedish Cohort Study Over 2 Decades.
Forsman LD, Jonsson J, Wagrell C, Werngren J, Mansjö M, Wijkander M, Groenheit R, Hammar U, Giske CG, Schön T, Bruchfeld J
Clin Infect Dis 2019;69:8

Diagnostic pathways and delay among tuberculosis patients in Stockholm, Sweden: a retrospective observational study.
Wikell A, Åberg H, Shedrawy J, Röhl I, Jonsson J, Berggren I, Buxbaum C, Lönnroth K, Bruchfeld J
BMC Public Health 2019;19:1

A new mathematical model to identify contacts with recent and remote latent tuberculosis.
Fröberg G, Wahren Borgström E, Chryssanthou E, Correia-Neves M, Källenius G, Bruchfeld J
ERJ Open Res 2019;5:2

Quality of life of patients on treatment for latent tuberculosis infection: a mixed-method study in Stockholm, Sweden.
Shedrawy J, Jansson L, Röhl I, Kulane A, Bruchfeld J, Lönnroth K
Health Qual Life Outcomes 2019;17:1

Sedimentation rate and suPAR in relation to disease activity and mortality in patients with tuberculosis.
Schulman H, Niward K, Abate E, Idh J, Axenram P, Bornefall A, Forsgren S, Jakobsson J, Öhrling C, Kron M, Brudin L, Diro E, Getachew Kebede A, Paues J, Bruchfeld J, Wejse C, Stendahl O, Schön T
Int J Tuberc Lung Dis 2019;23:11

Individualised dosing algorithm and personalised treatment of high-dose rifampicin for tuberculosis.
Svensson RJ, Niward K, Davies Forsman L, Bruchfeld J, Paues J, Eliasson E, Schön T, Simonsson USH
Br J Clin Pharmacol 2019;85:10

Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report.
Borisov S, Danila E, Maryandyshev A, Dalcolmo M, Miliauskas S, Kuksa L, Manga S, Skrahina A, Diktanas S, Codecasa LR, Aleksa A, Bruchfeld J, Koleva A, Piubello A, Udwadia ZF, Akkerman OW, Belilovski E, Bernal E, Boeree MJ, Cadiñanos Loidi J, Cai Q, Cebrian Gallardo JJ, Dara M, Davidavičienė E, Forsman LD, De Los Rios J, Denholm J, Drakšienė J, Duarte R, Elamin SE, Escobar Salinas N, Ferrarese M, Filippov A, Garcia A, García-García JM, Gaudiesiute I, Gavazova B, Gayoso R, Gomez Rosso R, Gruslys V, Gualano G, Hoefsloot W, Jonsson J, Khimova E, Kunst H, Laniado-Laborín R, Li Y, Magis-Escurra C, Manfrin V, Marchese V, Martínez Robles E, Matteelli A, Mazza-Stalder J, Moschos C, Muñoz-Torrico M, Mustafa Hamdan H, Nakčerienė B, Nicod L, Nieto Marcos M, Palmero DJ, Palmieri F, Papavasileiou A, Payen MC, Pontarelli A, Quirós S, Rendon A, Saderi L, Šmite A, Solovic I, Souleymane MB, Tadolini M, van den Boom M, Vescovo M, Viggiani P, Yedilbayev A, Zablockis R, Zhurkin D, Zignol M, Visca D, Spanevello A, Caminero JA, Alffenaar JW, Tiberi S, Centis R, D'Ambrosio L, Pontali E, Sotgiu G, Migliori GB
Eur Respir J 2019;54:6

2018

Deciphering the molecular basis of mycobacteria and lipoglycan recognition by the C-type lectin Dectin-2.
Decout A, Silva-Gomes S, Drocourt D, Blattes E, Rivière M, Prandi J, Larrouy-Maumus G, Caminade AM, Hamasur B, Källenius G, Kaur D, Dobos KM, Lucas M, Sutcliffe IC, Besra GS, Appelmelk BJ, Gilleron M, Jackson M, Vercellone A, Tiraby G, Nigou J
Sci Rep 2018;8:1

Risk factors of multidrug-resistant tuberculosis: A global systematic review and meta-analysis.
Pradipta IS, Forsman LD, Bruchfeld J, Hak E, Alffenaar JW
J Infect 2018;77:6

Plasma concentrations of second-line antituberculosis drugs in relation to minimum inhibitory concentrations in multidrug-resistant tuberculosis patients in China: a study protocol of a prospective observational cohort study.
Davies Forsman L, Niward K, Hu Y, Zheng R, Zheng X, Ke R, Cai W, Hong C, Li Y, Gao Y, Werngren J, Paues J, Kuhlin J, Simonsson USH, Eliasson E, Alffenaar JW, Mansjö M, Hoffner S, Xu B, Schön T, Bruchfeld J
BMJ Open 2018;8:9

Distribution of plasma concentrations of first-line anti-TB drugs and individual MICs: a prospective cohort study in a low endemic setting.
Niward K, Davies Forsman L, Bruchfeld J, Chryssanthou E, Carlström O, Alomari T, Carlsson B, Pohanka A, Mansjö M, Jonsson Nordvall M, Johansson AG, Eliasson E, Werngren J, Paues J, Simonsson USH, Schön T
J Antimicrob Chemother 2018;73:10

Geospatial distribution of Mycobacterium tuberculosis genotypes in Africa.
Chihota VN, Niehaus A, Streicher EM, Wang X, Sampson SL, Mason P, Källenius G, Mfinanga SG, Pillay M, Klopper M, Kasongo W, Behr MA, Gey van Pittius NC, van Helden PD, Couvin D, Rastogi N, Warren RM
PLoS One 2018;13:8

Genetic diversity and potential routes of transmission of Mycobacterium bovis in Mozambique.
Machado A, Rito T, Ghebremichael S, Muhate N, Maxhuza G, Macuamule C, Moiane I, Macucule B, Marranangumbe AS, Baptista J, Manguele J, Koivula T, Streicher EM, Warren RM, Kallenius G, van Helden P, Correia-Neves M
PLoS Negl Trop Dis 2018;12:1

Tuberculosis Risk in Ankylosing Spondylitis, Other Spondyloarthritis, and Psoriatic Arthritis in Sweden: A Population-Based Cohort Study.
de Vries MK, Arkema EV, Jonsson J, Bruchfeld J, Jacobsson LTH, Askling J, ARTIS Study Group.
Arthritis Care Res (Hoboken) 2018;70:10